title: Total androgen blockade with Zoladex plus flutamide vs. Zoladex alone in advanced prostatic carcinoma: interim report of a multicenter, double-blind, placebo-controlled study.
abstract: A double-blind, placebo-controlled, randomized, multicenter study was undertaken to investigate the effects of Zoladex plus flutamide vs. Zoladex plus placebo in patients with advanced prostatic cancer. Interim analysis has revealed no differences between the 2 groups in objective or subjective responses at 6 months' follow-up or in overall survival and time to disease progression at 15 months' follow-up.
authors: Service d'Urologie Centre Hospitalier, Auxerre, France.
authors: R O
authors: RO
authors: Fourcade
authors: G
authors: G
authors: Cariou
authors: P
authors: P
authors: Coloby
authors: P
authors: P
authors: Colombel
authors: C
authors: C
authors: Coulange
authors: P
authors: P
authors: Grise
authors: P
authors: P
authors: Mangin
authors: J Y
authors: JY
authors: Soret
authors: M
authors: M
authors: Poterre
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002064:Buserelin / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D004311:Double-Blind Method; D005485:Flutamide / Q000008:administration & dosage; D005500:Follow-Up Studies; D017273:Goserelin; D006801:Humans; D008297:Male; D008875:Middle Aged; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000401:mortality; D015996:Survival Rate
chemical_list: D017273:Goserelin; D005485:Flutamide; D002064:Buserelin